Mivacron (Mivacurium Chloride)

Mivacron, a neuromuscular blocking agent, is used to achieve temporary skeletal muscle relaxation in specific clinical settings.

• Endotracheal intubation: provides rapid muscle relaxation to facilitate tube placement.
• Surgical procedures: maintains muscle paralysis for optimal operative conditions.
• Brief diagnostic or therapeutic interventions: enables controlled muscle relaxation when short‑duration paralysis is required.

• Mivacurium chloride acts as a competitive antagonist at nicotinic acetylcholine receptors located on the motor end‑plate of the neuromuscular junction. By blocking acetylcholine binding, it prevents depolarization of the muscle membrane, resulting in a reversible loss of skeletal muscle tone and paralysis that can be rapidly reversed as the drug is hydrolyzed by plasma cholinesterases.

Mivacron may cause a range of adverse reactions after intravenous administration.

Common Side Effects

• Flushing: transient redness of the skin, often on the face or neck.
• Hypotension: mild to moderate drop in blood pressure.
• Tachycardia: increase in heart rate.
• Bronchospasm: transient narrowing of the airways, especially in susceptible patients.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate intervention.
• Prolonged apnea: extended respiratory paralysis beyond the expected duration.
• Malignant hyperthermia: rare hypermetabolic crisis triggered by certain anesthetics.
• Cardiac arrest: sudden loss of heart function.
• Severe hypotension: marked drop in blood pressure leading to organ hypoperfusion.
• Respiratory depression: significant reduction in breathing effort.

Before using Mivacron, clinicians should consider several safety measures.

• Assess patient history: verify absence of hypersensitivity to mivacurium or related neuromuscular blockers.
• Monitor neuromuscular function: use peripheral nerve stimulators to gauge depth of blockade.
• Evaluate plasma cholinesterase activity: patients with deficient enzymes may experience prolonged effects.
• Adjust dosing in the elderly or those with hepatic/renal impairment: consider slower metabolism.
• Maintain emergency airway equipment: be prepared for rapid re‑intubation if needed.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mivacron can interact with other agents that influence neuromuscular transmission or cardiovascular stability.

Major Interactions (Avoid)

• Aminoglycoside antibiotics: may potentiate neuromuscular blockade.
• Lithium: can enhance the paralytic effect.
• Magnesium sulfate: increases susceptibility to blockade.
• General anesthetics (e.g., propofol, volatile agents): additive depressant effect on respiration and muscle tone.

Moderate Interactions (Monitor Closely)

• Volatile inhalational agents: may prolong duration of paralysis.
• Beta‑adrenergic blockers: can affect hemodynamic response during blockade.